Amgen breaks ground on $200m biomanufacturing facility in US

07:13 EDT 1 Aug 2018 | Pharmaceutical Business Review

The company expects to invest up to $200m in the approximately 120,000ft² biomanufacturing plant at its West Greenwich campus in Rhode Island. Amgen will use its next-generation biomanufacturing

The post Amgen breaks ground on $200m biomanufacturing facility in US appeared first on Pharma Business review.

Original Article: Amgen breaks ground on $200m biomanufacturing facility in US

More From BioPortfolio on "Amgen breaks ground on $200m biomanufacturing facility in US"